share_log

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target

Benzinga ·  Nov 15, 2023 07:21

HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment